On August 17, 2022 Provectus (OTCQB: PVCT) reported that the Company has expanded its sponsored research program with Aru Narendran, MD, PhD, Professor, Departments of Pediatrics, Oncology, Biochemistry & Molecular Biology, and Physiology & Pharmacology at the Cumming School of Medicine of the University of Calgary in Calgary, Alberta, Canada to investigate systemic administration of Provectus’ pharmaceutical-grade rose bengal for the treatment of pediatric leukemia (Press release, Provectus Biopharmaceuticals, AUG 17, 2022, View Source [SID1234618460]). The Company’s innovatively-assembled and proprietary rose bengal is the lead member of a class of small molecules called halogenated xanthenes.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As part of this new sponsored research, the Narendran team plans to:
Identify clinically-feasible drug combinations and synthetic lethality that have synergistic activity with Provectus’ rose bengal,
Evaluate systemic drug administration routes for maximal tolerability,
Evaluate the modulation of WNK1 (lysine deficient protein kinase 1) and other related pathways induced by the Company’s rose bengal, and
Complete demonstration of STING (stimulator of interferon genes) dimerization in leukemia cells.
The Narendran team has previously shown:
In vitro activity and target modulation effects of Provectus’ rose bengal against several different pediatric leukemia‐derived cell lines and primary cells,
Proof‐of-concept of several potential mechanisms that may be involved in this process,
Rose bengal’s ability to induce STING dimerization and the molecule’s association with heat shock proteins, and
Preliminary evidence of in vivo activity in mouse xenograft models using the pediatric leukemia cell line SEM following oral doses of the Company’s rose bengal.